10 results for "Hye-Ryeon Kim"
Showing 1–10 · 0.74 seconds · RSS
-
Journal Article Full text
Exploring the knowledge structure of Korean physical activity research using topic modeling and keyword network analysis
Background and purpose: Information on topics and knowledge structures is an important indicator of trends, prospects and sustainability in research fields. Although many studies on physical activity (PA) have been published in Korea, no studies have been reported to explain knowledge structure…
-
Journal Article
The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
BackgroundTrastuzumab is a HER2-trargeted humanized monoclonal antibody that has been studied as a first-line treatment for patients with HER2-positive advanced gastric cancer (AGC). The effect of anti-HER2 therapy according to tumor mutational burden (TMB) in HER2-positive AGC remains…
-
Journal Article
Validation of the Korean Movement Culture Perception (KMCP) Scale Using the Rasch Model: Evidence from Korean and Chinese Populations [version 1; peer review: 2 approved]
Background This study validates the Korean Movement Culture Perception (KMCP) scale, a tool designed to assess Korea's 'Movement Culture' (e.g., K-pop dance, Taekwondo), a key element of the 'Shin Hallyu' (New Korean Wave) characterized by participatory consumption. Using the Rasch model, this…
-
Journal Article
Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer
Background: Expression of programmed death-ligand 1 (PD-L1) has been reported to correlate with response to immune checkpoint inhibitors (ICIs) in various tumor types. However, there are few data on the role of PD-L1 expression as a predictive and prognostic biomarker of sensitivity to ICIs in…
-
Journal Article
Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention
Abstract Chimeric antigen receptor (CAR) T-cell therapy is an established treatment for relapsed or refractory B-cell malignancies. Despite therapeutic success, infectious complications remain a major contributor to non-relapsed morbidity and mortality. The risk of infection reflects a prolonged…
-
Journal Article
Relationship between METS-IR and thyroid cancer incidence in Korea: a nationwide population-based study
BackgroundSeveral previous studies found a positive relationship between metabolic syndrome (MetS) and thyroid cancer (TC) risk. However, there is no research that has studied the relationship between the metabolic score for insulin resistance (METS-IR), a novel surrogate marker for IR, and TC…
-
Journal Article Full text
A Study on the Effectiveness of Korean Medicine Treatment for Patients’ Involved in Traffic Accidents and the Analysis of Factors Affecting the Effectiveness of Korean Medicine Treatment - A Retrospective Review
Background This study was conducted to verify the effectiveness and effectiveness-related factors of Korean medicine (KM) treatment for patients who have been involved in traffic accidents (TA). Methods The medical records of 150 TA patients hospitalized in Dongguk University Bundang Oriental…
-
Journal Article
HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer
HER2 aberrations have been reported as a novel biomarker in HER2-directed therapy or as a prognostic marker in various tumor types. However, in advanced biliary tract cancer (BTC), there have been few studies regarding HER2 aberrations as a biomarker. We analyzed 121 advanced BTC patients who had…
-
Journal Article
Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
Background : High tumor mutational burden (TMB-H) has been reported as a predictive marker to immunotherapy or prognostic marker in various tumor types. However, there has been little study of the role of TMB-H in advanced biliary tract cancer (BTC). Methods : We analyzed 119 advanced BTC patients…
-
Journal Article
A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma
PurposePatients with International Metastatic RCC Database Consortium (IMDC) poor risk metastatic renal cell carcinoma (mRCC) rarely respond to first-line tyrosine kinase inhibitors (TKIs) including sunitinib, and carries a very poor prognosis. In recent years, combination therapy involving immune…